Family Care Hospitals Valuation
Is 516110 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 516110 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 516110's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 516110's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 516110?
Key metric: As 516110 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 516110's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | ₹235.00m |
| Market Cap | ₹370.54m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 1.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 516110's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.1x | ||
NIDAN Nidan Laboratories and Healthcare | 1.8x | n/a | ₹403.8m |
526301 Medinova Diagnostic Services | 4.1x | n/a | ₹412.0m |
542918 Gian Life Care | 1.6x | n/a | ₹196.4m |
540788 Aspira Pathlab & Diagnostics | 4.8x | n/a | ₹729.8m |
516110 Family Care Hospitals | 1.6x | n/a | ₹370.5m |
Price-To-Sales vs Peers: 516110 is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (3.1x).
Price to Sales Ratio vs Industry
How does 516110's PS Ratio compare vs other companies in the IN Healthcare Industry?
| 8 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
MONOPHARMA Mono Pharmacare | 0.4x | n/a | US$7.33m |
542934 Chandra Bhagat Pharma | 0.3x | n/a | US$5.95m |
530697 Zenlabs Ethica | 0.5x | n/a | US$3.10m |
SAROJA Saroja Pharma Industries India | 0.6x | n/a | US$2.53m |
| 8 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 516110 is good value based on its Price-To-Sales Ratio (1.6x) compared to the Indian Healthcare industry average (3.9x).
Price to Sales Ratio vs Fair Ratio
What is 516110's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 516110's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Yatharth Hospital & Trauma Care Services
₹51.9b
Owns and operates super-specialty hospitals in Delhi and Madhya Pradesh.
543950
₹604.50
7D
0.02%
1Y
39.9%
Dr Lalchandani Labs
₹78.0m
Provides diagnostic and related healthcare tests and services in India.
541299
₹18.00
7D
-3.9%
1Y
n/a
N G Industries
₹565.2m
Provides various healthcare services in India.
530897
₹168.70
7D
-0.3%
1Y
0.8%